Epidemiology and effect of psychiatric comorbidities on survival rates in patients with systemic sclerosis: A nationwide population-based cohort study
Patients with SSc are at an increased risk of psychiatric comorbidities, which can negatively affect their survival rates. Treatment with a daily oral steroid dose of ≥7.5 mg, intravenous steroid pulse therapy, or D-penicillamine is a risk factor for psychiatric comorbidities in SSc.
Authors
- Yu‐Sheng Chang (ORCID: https://orcid.org/0000-0002-2622-7524)
- Yao‐Tung Lee (ORCID: https://orcid.org/0000-0003-2278-6369)
- Fangyi Wu
Institutions
- American University (US)
- Taipei Medical University Hospital (TW)
- Far Eastern Memorial Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- National Taipei University (TW)
Publication Details
- Journal
- Journal of Affective Disorders
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1016/j.jad.2025.04.104
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taipei Medical University